# US 2026/0092049 A1 · Methods of making trans isomeric forms of g protein-coupled receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092049 A1
- Document ID: US20260092049A1
- Status: Published application
- Kind: A1
- Application number: 19/320,950
- Filed: 2025-09-05
- Published: 2026-04-02
- Earliest claimed: 2021-02-02
- Assignees: Rapt Therapeutics, Inc.
- Applicants: Rapt Therapeutics, Inc.
- Inventors: Cyril Bucher; James P. Davidson; Jeffrey J. Jackson; Michelle Yoo Min Ko; Grant Shibuya; David J. Wustrow; Ashkaan Younai; Mikhail Zibinsky
- Web page: https://patentgrep.com/patent/US20260092049A1

## CPC

- C07D 401/14: containing three or more hetero rings
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed herein, inter alia, methods of synthesis of trans isomeric forms of G protein-coupled receptor modulators of high trans isomeric purity.

## Claims

### Claim 1

A method of synthesis of a compound of formula (VI), said method comprising reacting a compound of formula (I) with a compound of formula (II) in the presence of a carboxylic acid directed reducing agent to form the compound of formula (III), wherein:
the compound of formula (I) is:
the compound of formula (II) is:
the compound of formula (III) is:
and
further comprising forming a compound of formula (VI) from the compound of formula (III), wherein the compound of formula (VI) is:
wherein
n1′ is 1 and n2′ is 1;
L1′ is C(R4′)2;
L2′ is C(R5′)2;
R1′ is unsubstituted methyl;
R4′ is hydrogen;
R5′ is hydrogen;
R11′ is —CF3, —CHF2, —CH2F, —CCl3, —CHCl2, —CH2Cl, —CBr3, —CHBr2, —CH2Br, —CI3, —CHI2, —CH2I, —NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R12′ is —OH or —NHR12″;
R12″ is hydrogen or a substituted or unsubstituted alkyl;
z4 is 1;
X2 is CR9;
R1 and R2 are independently hydrogen or substituted or unsubstituted alkyl;
R3.2 and R3.3 are independently halogen or substituted or unsubstituted alkyl;
R4 is halogen or substituted or unsubstituted alkyl;
R9 is hydrogen, —CX9.13, —CHX9.12, —CH2X9.1, or substituted or unsubstituted alkyl;
X9.1 is independently —Cl, —Br, —I or —F;
R44 is hydrogen; and
-L7-R7 is:

### Claim 2 (depends on 1)

The method of claim 1, wherein the method is used to make an antagonist of C—C chemokine receptor type 4 (CCR4), or a salt or ester thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of formula (III) is in at least 80% trans isomerically pure form.

### Claim 4 (depends on 1)

The method of claim 1, wherein the carboxylic acid directed reducing agent is a 1,4-dihydropyridine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the carboxylic acid directed reducing agent is the 1,4-dihydropyridine of formula (IV):
wherein:
L3′ and L4′ are independently —O—;
R6′ is substituted or unsubstituted alkyl;
R7′ is substituted or unsubstituted alkyl;
R8′ is substituted or unsubstituted alkyl;
R9′ is hydrogen; and
R10′ is substituted or unsubstituted alkyl.

### Claim at position 6

-14. (canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein R11′ is a substituted or unsubstituted alkyl.

### Claim 16 (depends on 15)

The method of claim 15, wherein R11′ is a substituted or unsubstituted C1-C4 alkyl.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1,
wherein R11′ is t-butyl or benzyl.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the compound of formula (VI) is selected from:
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The method of claim 1, wherein R4 is halogen.

### Claim 22 (depends on 1)

The method of claim 1, wherein R9 is hydrogen or unsubstituted methyl.
